PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options ...

PTC Inc. has underperformed its software peers over the past year, and analysts are somewhat optimistic about the stock’s ...

Shares of PTC Inc. PTC shed 2.94% to $167.53 Tuesday, on what proved to be an all-around rough trading session for the stock ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the 10 biotech stocks screaming a buy. On June 17, analysts at Truist ...

Shares of PTC Inc. PTC advanced 1.93% to $172.61 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.94% to 6,033.11 and the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United ...

Fintel reports that on June 17, 2025, Truist Securities initiated coverage of PTC Therapeutics (NasdaqGS:PTCT) with a Buy recommendation. Analyst Price Forecast Suggests 22.69% Upside As of June 2, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...

Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...